Hepatology News Tonight - Managing Complications of Cirrhosis

This activity was recorded at a satellite symposium event concurrent with the 2018 SHM Annual Conference. This educational content was developed and hosted by Focus Med Ed.

Program Overview

Experts estimate that 5.5 million people in the United States have cirrhosis.  At the time of diagnosis, 10-14% of patients with cirrhosis, 16-21% of patients with decompensated cirrhosis, and 10-50% of patients with transjugular intrahepatic portosystemic shunt will have overt hepatic encephalopathy (OHE). Twenty to 80% of patients with cirrhosis can expect to experience either covert hepatic encephalopathy (CHE) or OHE during the course of their disease. These levels of prevalence highlight the need for physicians to be alert to the possibility of patients with chronic liver disease having hepatic encephalopathy (HE).

This educational update will highlight the most clinically relevant advances in the management of patients with cirrhosis and HE. We hope that the webcast is informative and that the knowledge, experience, and insights we share with you are useful in your treatment of patients with chronic liver disease.

We gratefully acknowledge Salix Pharmaceuticals, Inc. for their educational grant support of this educational activity.

Target Audience

This activity has been designed to meet the educational needs of physicians, advanced practice providers and allied health professionals who provide care for hospitalized patients with  liver disease.

Learning Objectives

After completing this enduring activity, participants should be better able to:

  • Understand the complications and the consequences of chronic liver disease
  • Describe the economic, patient and caregiver burdens associated with cirrhosis and HE
  • Demonstrate the ability to properly treat HE patients and prevent recurrence of disease

Statement of Need:

The goal of this enduring activity is to provide important clinical and scientific data on the management of CLD.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the New Mexico Medical Society (NMMS) through the joint providership of Rehoboth McKinley Christian Health Care Services (RMCHCS), the Chronic Liver Disease Foundation (CLDF) and the Texas Gulf Coast Gastroenterological Society (TGCGS). RMCHCS is accredited by the NMMS to provide continuing medical education for physicians.

RMCHCS designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Supported by an educational grant from Salix Pharmaceuticals.

ADDITIONAL INFORMATION

REQUIRED HARDWARE / SOFTWARE: 

  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.

Copyright © 2018 No part of this publication may be produced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical photocopying, recording, or otherwise, without the prior permission of the publisher

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-physician
Course opens: 
05/22/2018
Course expires: 
06/22/2019
Member cost:
$0.00
Your cost:
$0.00

About our Faculty
Naoky Tsai, MD, is currently a clinical professor of medicine and chief of the section of Hepatobiliary Disease, Division of Gastroenterology, Department of Medicine, John A. Burns School of Medicine (JABSOM), University of Hawaii, Honolulu, Hawaii, USA.

Dr. Tsai’s research interest is on natural history and the consequences of chronic liver disease, NASH and NAFLD, risk for disease progression, and prevention of hepatic decompensation and hepatocellular carcinoma (HCC) development. He received an NIH/NCI grant (1RO1 NIH/NCI CA161209-01) as part of UH Cancer Center’s effort to start a translational clinical research protocol to study the epidemiology and unmet need of the underserved minority group of Asian-Pacific Islanders (APIs) and to conduct a clinical trial for the prevention and control of viral hepatitis and HCC. Over the last 20 years, he has been dedicated to the management and study of chronic liver disease. He was awarded by NIH/NIDDK an UO1 grant-DK082863 (F021481) to participate in a Clinical Research Network for Chronic Hepatitis B and has conducted multiple clinical trials for chronic hepatitis B, chronic hepatitis C, and HCC with publications in peer-reviewed Journals. Dr. Tsai has conducted prevalence studies of chronic hepatitis in Hawaii raising the issues of unmet medical need of API in Hawaii. In addition, he started a multidisciplinary conference on a biweekly basis for hepatobiliary tumor to deal with clinical decisions on the ever-increasing demand of liver cancer management since 2008.

Dr. Tsai has served as reviewer of multiple peer-reviewed medical journals including Hepatology, Journal of Hepatology, Gastroenterology, Clinical Gastroenterology and Hepatology to name a few. He has also served as a guest editor of Clinic of Liver Disease.

Dr. Tsai has published multiple original research articles in peer-reviewed journals such as NEJM, Hepatology, Gastroenterology, Journal of Hepatology, etc.

Dr. Tsai has disclosed the following relevant financial relationships:
Speaker Bureau: AbbVie, BMS, Gilead, Merck, Intercept, and Salix Pharmaceuticals
Honoraria recipient: AbbVie, BMS, Gilead, Merck, Intercept, and Salix Pharmaceuticals

Ashwani K. Singal, MD, MS, FACG, FAASLD, is associate professor of medicine in the Division of Gastroenterology and Hepatology and director of the Porphyria Center at the University of Alabama at Birmingham (UAB). With his interests in alcoholic and non-alcoholic fatty liver diseases and porphyria, he has over 150 original articles and book chapters to his credit. He is associate editor of the Journal of Clinical and Translational Hepatology and European Medical Journal, and active editorial board member for Liver Transplantation and Journal of Hepatology (ALD section). As an active executive member of the ACG practice parameters committee, AGA research awards panel, the AASLD Research Awards Committee, and Steering Committee member of ALD Special Interest Group of the AASLD, Dr. Singal has led the group in writing practice guidelines for alcoholic liver disease for the ACG. Apart from the pharmaceutical industry, his clinical and translational research is funded by the UAB, the American College of Gastroenterology, and NIDDK and NIAAA of the NIH.

Dr. Singal has no relevant financial relationships to disclose.

Statement of Need:

The goal of this enduring activity is to provide important clinical and scientific data on the management of CLD.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the New Mexico Medical Society (NMMS) through the joint providership of Rehoboth McKinley Christian Health Care Services (RMCHCS), the Chronic Liver Disease Foundation (CLDF) and the Texas Gulf Coast Gastroenterological Society (TGCGS). RMCHCS is accredited by the NMMS to provide continuing medical education for physicians.

RMCHCS designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-physician

Accreditation Period

Course opens: 
05/22/2018
Course expires: 
06/22/2019

Price

Member cost:
$0.00
Your cost:
$0.00
Please login or register to take this course.